Cargando…

Clinical Determinants of Successful Omalizumab Therapy in Severe Allergic Asthma Patients: 4-Year-Long, Real-Life Observation

INTRODUCTION: Omalizumab is a high-cost therapy recommended for the treatment of severe allergic asthma. OBJECTIVE: To find clinical parameters that are related to the sustained response to omalizumab. PATIENTS AND METHODS: This retrospective, real-life, 4-year follow-up was provided in Poland betwe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kucharczyk, Aleksandra, Więsik-Szewczyk, Ewa, Poznańska, Anna, Jahnz-Różyk, Karina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754267/ https://www.ncbi.nlm.nih.gov/pubmed/33363390 http://dx.doi.org/10.2147/JAA.S282203

Ejemplares similares

Clinical and economic impact of a one-year treatment with omalizumab in patients with severe allergic asthma within a drug programme in Poland
por: Jahnz-Różyk, Karina, et al.
Publicado: (2018)

A case report of pregnancy in a patient with common variable immunodeficiency emphasizing the need for personalized immunoglobulin replacement
por: Więsik-Szewczyk, Ewa, et al.
Publicado: (2018)

From infections to autoimmunity: Diagnostic challenges in common variable immunodeficiency
por: Więsik-Szewczyk, Ewa, et al.
Publicado: (2020)

Facilitated Subcutaneous Immunoglobulin Replacement Therapy in Clinical Practice: A Two Center, Long-Term Retrospective Observation in Adults With Primary Immunodeficiencies
por: Wiesik-Szewczyk, Ewa, et al.
Publicado: (2020)

Periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome persisting to adulthood – an example of a diagnostic and therapeutic challenge
por: Więsik-Szewczyk, Ewa, et al.
Publicado: (2019)

Schnitzler Syndrome in a 27-Year-Old Man: Diagnostic and Therapeutic Dilemma in Adult Auto-Inflammatory Syndromes A Case Report and Literature Review
por: Więsik-Szewczyk, Ewa, et al.
Publicado: (2020)

Increased Access to Immunoglobulin Replacement Therapy for Patients with Primary Immunodeficiency in Poland Based on Clinical Usage Data of Immunoglobulin G over a 5-Year Period
por: Więsik-Szewczyk, Ewa, et al.
Publicado: (2023)

Shorter Diagnostic Delay in Polish Adult Patients With Common Variable Immunodeficiency and Symptom Onset After 1999
por: Ziętkiewicz, Marcin, et al.
Publicado: (2020)

Patients with Common Variable Immunodeficiency Complicated by Autoimmune Phenomena Have Lymphopenia and Reduced Treg, Th17, and NK Cells
por: Więsik-Szewczyk, Ewa, et al.
Publicado: (2021)

Analysis of Leukocyte Subpopulations by Flow Cytometry during Hospitalization Depending on the Severity of COVID-19 Course
por: Rutkowska, Elżbieta, et al.
Publicado: (2023)

Early impact of treatment with tiotropium, long-acting anticholinergic preparation, in patients with COPD – real-life experience from an observational study
por: Jahnz-Różyk, Karina, et al.
Publicado: (2015)

Omalizumab in Children with Severe Allergic Asthma: The Italian Real-Life Experience
por: Licari, Amelia, et al.
Publicado: (2017)

Maturation of T and B Lymphocytes in the Assessment of the Immune Status in COVID-19 Patients
por: Kwiecień, Iwona, et al.
Publicado: (2020)

Secondary immunodeficiencies with predominant antibody deficiency: multidisciplinary perspectives of Polish experts
por: JAHNZ-RÓŻYK, KARINA, et al.
Publicado: (2020)

Comparison of pulmonary lesions using lung ultrasound and high-resolution computed tomography in adult patients with primary humoral immunodeficiencies
por: Ziętkiewicz, Marcin, et al.
Publicado: (2022)

Coronavirus disease 2019 vaccination uptake and hesitancy among Polish patients with inborn errors of immunity, autoinflammatory syndromes, and rheumatic diseases: A multicenter survey
por: Więsik-Szewczyk, Ewa, et al.
Publicado: (2022)

Real-life Effectiveness of Omalizumab in Patients with Severe Allergic Asthma: RELIEF Study
por: Al Ahmad, Mona, et al.
Publicado: (2022)

Effect of influenza vaccinations on immune response and serum eotaxin level in patients with allergic bronchial asthma.
por: Jahnz-Rózyk, Karina, et al.
Publicado: (2004)

Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study
por: Canonica, Giorgio Walter, et al.
Publicado: (2018)

Omalizumab for Severe Asthma: Beyond Allergic Asthma
por: Loureiro, C. C., et al.
Publicado: (2018)

Omalizumab for severe allergic asthma: a life changing drug?
por: Mesonjesi, Eris, et al.
Publicado: (2015)

A New Outlook on the Ability to Accumulate an Iodine Contrast Agent in Solid Lung Tumors Based on Virtual Monochromatic Images in Dual Energy Computed Tomography (DECT): Analysis in Two Phases of Contrast Enhancement
por: Zegadło, Arkadiusz, et al.
Publicado: (2021)

Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
por: Torres-Duque, Carlos A., et al.
Publicado: (2022)

Real-World Observational Study on the Characteristics and Treatment Patterns of Allergic Asthma Patients Receiving Omalizumab in Canada
por: Lee, Jason K, et al.
Publicado: (2020)

In search of clinically relevant parameters to monitor successful omalizumab therapy in allergic asthma
por: Probst, M., et al.
Publicado: (2019)

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
por: Snelder, S. M., et al.
Publicado: (2017)

Dual-energy computed tomography as a lower radiation dose alternative to perfusion computed tomography in tumor viability assessment
por: Zegadło, Arkadiusz, et al.
Publicado: (2023)

282 Successful Treatment of Severe Nonallergic Asthma by Omalizumab. An Observation
por: Bergmann, Karl-Christian, et al.
Publicado: (2012)

The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study
por: Bhutani, Mohit, et al.
Publicado: (2017)

Successful treatment of severe allergic asthma with omalizumab in a girl with DiGeorge syndrome
por: JESENAK, MILOS, et al.
Publicado: (2020)

The effect of omalizumab treatment on severe allergic asthma and allergic comorbidities: real-life experience from the Czech Anti-IgE Registry
por: Hutyrová, Beáta, et al.
Publicado: (2018)

Effectiveness of Omalizumab in Severe Allergic Asthma: A Retrospective UK Real-World Study
por: Barnes, Neil, et al.
Publicado: (2013)

Omalizumab: the evidence for its place in the treatment of allergic asthma
por: McNicholl, Diarmuid M., et al.
Publicado: (2008)

Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma
por: Kotoulas, Serafeim Chrysovalantis, et al.
Publicado: (2022)

Omalizumab and IgE in the Control of Severe Allergic Asthma
por: Gon, Yasuhiro, et al.
Publicado: (2022)

Omalizumab for Chinese patients with moderate-to-severe allergic asthma in real-world clinical setting: a prospective, observational study
por: Wang, Wen, et al.
Publicado: (2023)

Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting
por: Braunstahl, Gert-Jan, et al.
Publicado: (2013)

Healthcare Resource Utilization in Patients Receiving Omalizumab for Allergic Asthma in a Real-World Setting
por: Braunstahl, Gert-Jan, et al.
Publicado: (2014)

COVID-19 Pandemic and Patients with Rare Inherited Metabolic Disorders and Rare Autoinflammatory Diseases—Organizational Challenges from the Point of View of Healthcare Providers
por: Tobór-Świętek, Ewa, et al.
Publicado: (2021)

Omalizumab in the management of patients with allergic (IgE-mediated) asthma
por: Sandström, Thomas
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_608uopfof9f9f46fod7d0l8bbr